FDA approves Radius Health osteoporosis drug, but adds cancer warning
The FDA on Friday approved an osteoporosis drug made by Waltham-based Radius Health, but added a so-called "black box" warning that the treatment had increased the risk of bone cancer in rats.
Radius (Nasdaq: RDUS) is hoping that abaloparatide, which will be sold under the brand name Tymlos, will eventually take on Forteo, an osteoporosis treatment sold by Eli Lilly (NYSE: LLY) that generated $1.5 billion in sales last year. Forteo has the same warning, which states that the drug increa sed the risk… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - April 28, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
FDA approves Radius Health osteoporosis drug, but adds cancer warning
The FDA on Friday approved an osteoporosis drug made by Waltham-based Radius Health, but added a so-called "black box" warning that the treatment had increased the risk of bone cancer in rats.
Radius (Nasdaq: RDUS) is hoping that abaloparatide, which will be sold under the brand name Tymlos, will eventually take on Forteo, an osteoporosis treatment sold by Eli Lilly (NYSE: LLY) that generated $1.5 billion in sales last year. Forteo has the same warning, which states that the drug increa sed the risk… (Source: bizjournals.com Health Care:Physician Practices headlines)
Source: bizjournals.com Health Care:Physician Practices headlines - April 28, 2017 Category: American Health Authors: Max Stendahl Source Type: news
Waltham-based Radius Health faces 3-month delay on drug approval
Radius Health suffered a setback Friday when the FDA delayed the potential approval of an osteoporosis drug that the Waltham biotech hopes will eventually take on Eli Lilly ’s $1.5 billion a year treatment Forteo.
Radius (Nasdaq: RDUS) said in a statement Friday that the agency had moved its target approval date for the drug, called abaloparatide, from March 30 to June 30. According to Radius, regulators told the company on Thursday that they needed more time to rev iew additional information in… (Source: bizjournals.com Health Care:Biotechnology headlines)
Source: bizjournals.com Health Care:Biotechnology headlines - March 10, 2017 Category: Biotechnology Authors: Max Stendahl Source Type: news
NovoLog Mix 70/30 (Insulin Aspart Protamine and Insulin Aspart (rDNA origin)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - February 2, 2017 Category: Drugs & Pharmacology Source Type: news
Glide raises $4m for phase I trial of solid-dose teriparatide
Glide Technologies said today that it raised £3.2 million, or $4.0 million USD, in a round of financing. A number of existing investors contributed to the round, according to the Oxford-based company.
Glide plans to use the funds to finish phase I trials this year for its solid dose formulation of a parathyroid hormone, teriparatide.
Get the full story at our sister site, Drug Delivery Business News.
The post Glide raises $4m for phase I trial of solid-dose teriparatide appeared first on MassDevice. (Source: Mass Device)
Source: Mass Device - February 1, 2017 Category: Medical Equipment Authors: Sarah Faulkner Tags: Funding Roundup Pharmaceuticals Wall Street Beat Glide Technologies Source Type: news
For Patients With Atypical Femur Fractures, Teriparatide Improves Bone Health For Patients With Atypical Femur Fractures, Teriparatide Improves Bone Health
Teriparatide may improve the bone health of patients with atypical femur fractures (AFFs) who ' ve taken bisphosphonates, but doctors shouldn ' t depend on the drug to help heal the fractures, a new prospective study suggests.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 30, 2017 Category: Consumer Health News Tags: Orthopaedics News Source Type: news
New clinical trial to test drug combination to treat osteogenesis imperfecta
The University of Edinburgh will conduct a six-year trial of teriparatide and zoledronic acid combination to treat a condition called osteogenesis imperfecta (OI). (Source: Drug Development Technology)
Source: Drug Development Technology - January 18, 2017 Category: Pharmaceuticals Source Type: news
Increlex (Mecasermin [rDNA origin] Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 5, 2017 Category: Drugs & Pharmacology Source Type: news
Exubera (Insulin Human [rDNA origin]) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - January 5, 2017 Category: Drugs & Pharmacology Source Type: news
Humatrope (Somatropin rDNA Origin) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news
Genotropin (Somatropin [rDNA origin]) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news
Serostim (Somatropin (rDNA origin)) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - December 15, 2016 Category: Drugs & Pharmacology Source Type: news
Saxenda (Liraglutide [rDNA Origin]) Injection) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 14, 2016 Category: Drugs & Pharmacology Source Type: news
EMA Okays LixiLan Plus Biosimilars for Osteoporosis and Diabetes EMA Okays LixiLan Plus Biosimilars for Osteoporosis and Diabetes
The EMA has given a green light to new diabetes medicines, including LixiLan and a new biosimilar version of insulin glargine, as well as two biosimilar versions of teriparatide for osteoporosis.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - November 11, 2016 Category: Consumer Health News Tags: Diabetes & Endocrinology News Alert Source Type: news
NovoLog (Insulin Aspart [rDNA origin] Inj) - updated on RxList
(Source: RxList - New and Updated Drug Monographs)
Source: RxList - New and Updated Drug Monographs - November 10, 2016 Category: Drugs & Pharmacology Source Type: news
